AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10827213
Drug: High fruit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High fruit and vegetable diet (500g daily)
Trial: 10827213
Drug: Low fruit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low fruit and vegetable diet (100g daily)
Trial: 8893577
Drug: 99mTc-labeled monoclonal
RxNorm normalized name: technetium (99mTc) exametazime labelled cells
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 99mTc-labeled monoclonal granulocyte antibody scintigraphy
Trial: 8893577
Drug: 99mTc-labeled monoclonal
RxNorm normalized name: technetium (99mTc) exametazime labelled cells
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 99mTc-labeled monoclonal granulocyte antibody scintigraphy combined with tomographic scan
Trial: 1671468
Drug: Intravenous cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cyclophosphamide and oral prednisone (n = 55)
Trial: 1671468
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral cyclophosphamide, alternate day prednisone (22 weeks), and weekly plasma exchange (20 weeks) (n = 57)
Trial: 1671468
Drug: Placebo medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo medications and sham plasma exchange (n = 56)
Trial: 6839914
Drug: High fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High fluid regimen (172 +/- 25 ml/kg/day)
Trial: 6839914
Drug: Low fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low fluid regimen (121 +/- 13 ml/kg/day)
Trial: 31533539
Drug: Oral maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral maintenance group
Trial: 24977716
Drug: Atomoxetine (80-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atomoxetine (80-100 mg/d)
Trial: 15764277
Drug: Topical steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical steroid (betamethasone), applied twice daily for 4 weeks
Trial: 15764277
Drug: Topical steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical steroid (betamethasone) after 4 weeks for non-responders
Trial: 12475833
Drug: HFA‐BDP, 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HFA‐BDP, 80 micro g/d
Trial: 12475833
Drug: HFA‐BDP, 160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HFA‐BDP, 160 micro g/d
Trial: 3401697
Drug: OWLS (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OWLS (oral and written language training)
Trial: 3401697
Drug: Classroom survival
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Classroom survival skills (alternative treatment control)
Trial: 30625189
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (BCP + B. infantis)
Trial: 27837387
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin D3 (≤3 doses of 100,000 IU)
Trial: 27837387
Drug: Placebo (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (control group) with maintenance dose (3420 IU/day)
Trial: 27837387
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin D3 (loading dose)
Trial: 23424159
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (IFN β‐1a 30 μg intramuscularly weekly + glatiramer acetate 20 mg daily)
Trial: 23424159
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (IFN + GA)
Trial: 21955196
Drug: Ramelteon (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramelteon (all doses)
Trial: 21955196
Drug: Ramelteon (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramelteon (up to 8 mg)
Trial: 19203773
Drug: Free iron/folic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Free iron/folic acid tablets (IFA)
Trial: 19203773
Drug: Routine prenatal
RxNorm normalized name: Ardisia crenata root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine prenatal visits with prescriptions to purchase IFA
Trial: 11695069
Drug: Naproxen 250
RxNorm normalized name: naproxen 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 250 mg morning, 500 mg evening
Trial: 9137848
Drug: Lamotrigine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamotrigine (200 mg/day, with slow dose-escalation starting at 25 mg/day for 2 weeks, then 50 mg/day for 2 weeks)
Trial: 7899583
Drug: High-dose 1‐alpha‐OHD3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose 1‐alpha‐OHD3 plus 24,25(OH)2D3 (2 x 5 micrograms/day)
Trial: 7899583
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with 1‐alpha‐OHD3
Trial: 3035960
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of fenoterol (50 micrograms, 2 puffs, 4 times a day for 2.5 weeks)
Trial: 2198436
Drug: 7 g
RxNorm normalized name: Vaporizer 1.7 gallon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 g of olestra twice a day
Trial: 26044291
Drug: Oral Tenofovir
RxNorm normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral Tenofovir Disoproxil Fumarate (TDF)
Trial: 26044291
Drug: Vaginal Tenofovir
RxNorm normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Vaginal Tenofovir (TFV) gel
Trial: 26044291
Drug: Placebo (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (oral or vaginal)
Trial: 23704191
Drug: Intravenous clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous clonidine (3 μg kg(‐1)) plus wound infiltration with 30 ml of 0.25% bupivacaine
Trial: 23704191
Drug: Wound infiltration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wound infiltration with 3 μg kg(‐1) clonidine plus 30 ml of 0.25% bupivacaine
Trial: 23704191
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (wound infiltration with 30 ml of 0.25% bupivacaine)
Trial: 23704191
Drug: Intravenous clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous clonidine (3 μg kg(‐1))
Trial: 23704191
Drug: Wound infiltration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wound infiltration with 3 μg kg(‐1) clonidine
Trial: 17200793
Drug: Family Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family Therapy
Trial: 15161773
Drug: Repaglinide (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repaglinide (0.5 mg/meal, maximum dose 4 mg/meal)
Trial: 15161773
Drug: Nateglinide (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nateglinide (60 mg/meal, maximum dose 120 mg/meal)
Trial: 3364800
Drug: Adrenaline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenaline infusion (AI) after placebo (Pl) pretreatment
Trial: 3364800
Drug: Adrenaline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenaline infusion (AI) after diltiazem (D) pretreatment
Trial: 3364800
Drug: Adrenaline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenaline infusion (AI) after verapamil (V) pretreatment
Trial: 21177180
Drug: Cisatracurium infusion
RxNorm normalized name: Cisatracurium
DrugBank: Cisatracurium (DB00565)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisatracurium infusion with continuous monitoring of T1, adjusted according to muscle relaxation monitoring.
Trial: 8597678
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine oestrogen 625 micrograms daily alone
Trial: 8597678
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine oestrogen 625 micrograms daily plus norgestrel 150 micrograms daily for the last 12 days of the 'cycle'
Trial: 6760961
Drug: Weekly BCG
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly BCG and leukemia cell vaccine (group 1)
Trial: 6760961
Drug: Monthly BCG
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly BCG and leukemia cell vaccine (group 2)
Trial: 6760961
Drug: Monthly BCG
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly BCG with no leukemia cell vaccine (group 3)
Trial: 29914954
Drug: LR-BAC (Low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LR-BAC (Low dose rabeprazole 10 mg b.i.d. + bismuth + amoxicillin + clarithromycin)
Trial: 29914954
Drug: LR-BAT (Low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LR-BAT (Low dose rabeprazole 10 mg b.i.d. + bismuth + amoxicillin + tetracycline)
Trial: 29914954
Drug: HR-BAC (High
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HR-BAC (High dose rabeprazole 20 mg b.i.d. + bismuth + amoxicillin + clarithromycin)
Trial: 29914954
Drug: HR-BAT (High
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HR-BAT (High dose rabeprazole 20 mg b.i.d. + bismuth + amoxicillin + tetracycline)
Trial: 15803051
Drug: Antibiotics plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics plus IVIG (Pentaglobin; 7 mL/kg/day for 5 days)
Trial: 15803051
Drug: Antibiotics plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics plus 5% human albumin (control group)
Trial: 2218657
Drug: Cefuroxime axetil
RxNorm normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefuroxime axetil (CAE), 30 mg/kg/day
Trial: 2218657
Drug: Cefaclor (CEC),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefaclor (CEC), 40 mg/kg/day
Trial: 2218657
Drug: Amoxicillin-clavulanate potassium
RxNorm normalized name: amoxicillin / clavulanate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin-clavulanate potassium (AMX-CL), 40 mg/kg/day
Trial: 2218657
Drug: Amoxicillin-clavulanate potassium
RxNorm normalized name: amoxicillin / clavulanate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin-clavulanate potassium (AMX-CL)
Trial: 348125
Drug: Low sodium
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low sodium glucose electrolyte solution (sodium concentration of 50 mmol/l)
Trial: 348125
Drug: Standard oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard oral solution (sodium concentration of 90 mmol/l)
Trial: 23281658
Drug: Ramosetron 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramosetron 6 μg·kg(‐1)
Trial: 23281658
Drug: Ondansetron 100
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ondansetron 100 μg·kg(‐1)
Trial: 23281658
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups received intravenous patient-controlled analgesia with fentanyl
Trial: 22106196
Drug: Oral levofloxacin
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral levofloxacin plus normal saline wound irrigation
Trial: 22106196
Drug: Oral levofloxacin
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral levofloxacin plus Microcyn Rx wound irrigation
Trial: 17585038
Drug: 25 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 g/d of FS
Trial: 17585038
Drug: 50 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 g/d of FS
Trial: 17585038
Drug: 72 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 72 g/d of CSB
Trial: 15482245
Drug: Ultrasound therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound therapy (1 MHz, 1.0 W/cm², pulse 1:4, 15 min/session)
Trial: 15482245
Drug: Low level
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low level laser therapy (9 joules, 830 nm infrared laser at five points)
Trial: 11136956
Drug: Vapreotide (50-microg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vapreotide (50-microg intravenous bolus followed by an infusion at a rate of 50 microg per hour for five days)
Trial: 11136956
Drug: Vapreotide and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vapreotide and endoscopic treatment
Trial: 11136956
Drug: Endoscopic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic treatment alone
Trial: 7018328
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (usual treatment by emergency department nurses and residents)
Trial: 31530666
Drug: Oral Semaglutide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Semaglutide 14 mg
Trial: 15554315
Drug: Combined vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined vaccine 'Bubo-Kok'
Trial: 11447364
Drug: MCT oil
RxNorm normalized name: Organic MCT Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MCT oil (60 g daily for 2 weeks)
Trial: 11447364
Drug: LCT (corn
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCT (corn oil, 56 g daily for 2 weeks)
Trial: 4009848
Drug: Specific operative
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific operative procedures (subclavian-vertebral roof-patch angioplasty, reimplantation, carotid-vertebral vein bypass, decompression)
Trial: 31204328
Drug: Vital single
RxNorm normalized name: Vital-Chlor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vital single visit root canal treatment
Trial: 31204328
Drug: Necrotic single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Necrotic single visit root canal treatment
Trial: 31204328
Drug: Standardized preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized preparation technique
Trial: 29551340
Drug: Influenza vaccine
RxNorm normalized name: Influenza vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Influenza vaccine offered in the intervention group
Trial: 29551340
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no vaccine offered)
Trial: 19945816
Drug: Intensive telephone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive telephone counseling (bi-weekly)
Trial: 19945816
Drug: Less intensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Less intensive telephone counseling (monthly)
Trial: 12389338
Drug: Acarbose 50
RxNorm normalized name: acarbose 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acarbose 50 mg 3 times a day for 12 days (administered on day 8 before digoxin)
Trial: 12389338
Drug: Digoxin 0.75
RxNorm normalized name: digoxin 0.75 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digoxin 0.75 mg (administered alone)
Trial: 10430713
Drug: Inhibition of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhibition of deep inspiration after three doses of methacholine
Trial: 10430713
Drug: Inhibition of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhibition of deep inspiration after four doses of methacholine
Trial: 1934686
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of hyaluronic acid administered intra-articularly once a week for 3 weeks
Trial: 1934686
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of 6-methylprednisolone acetate administered intra-articularly once a week for 3 weeks
Trial: 6179650
Drug: Dibromodulcitol 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dibromodulcitol 10 mg/kg PO weekly for 8 weeks plus bleomycin 15 mu/m2 (initially three times weekly, later changed to twice weekly for 8 weeks)
Trial: 6179650
Drug: Bleomycin 15
RxNorm normalized name: bleomycin 15 UNT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bleomycin 15 mu/m2 (initially three times weekly, later changed to twice weekly for 8 weeks)
Trial: 29417850
Drug: Ginger root
RxNorm normalized name: Ginger Root
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginger root powder (0.5 g, 2 capsules per day, 0.25 g per capsule, every 12 hours for 5 days)
Trial: 27100399
Drug: Prebiotic arabinoxylan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prebiotic arabinoxylan oligosaccharides (AXOS) 10 g twice daily
Trial: 14981335
Drug: High-dose Hypericum
RxNorm normalized name: Hypericum oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose Hypericum perforatum extract WS 5570 (600, 900, and 1,200 mg)
Trial: 9827425
Drug: Salbutamol (0.5%‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (0.5%‐1 cc) every 12 h + Placebo every 12 h
Trial: 7816287
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (lithium carbonate 750 mg, 20 mmol)
Trial: 3075724
Drug: Desipramine 150
RxNorm normalized name: desipramine 150 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desipramine 150 mg/day
Trial: 3075724
Drug: Metapramine 450
RxNorm normalized name: mosapramine
DrugBank: Mosapramine (DB13676)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Metapramine 450 mg/day
Trial: 12362923
Drug: Ebastine 20
RxNorm normalized name: ebastine
DrugBank: Ebastine (DB11742)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ebastine 20 mg once daily with food
Trial: 12362923
Drug: Ebastine 20
RxNorm normalized name: ebastine
DrugBank: Ebastine (DB11742)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ebastine 20 mg once daily without food
Trial: 2089926
Drug: Nimodipine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimodipine (2 mg per hour intravenously for 7 days)
Trial: 444345
Drug: suxamethonium 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: suxamethonium 0.2 mg kg‐1
Trial: 444345
Drug: suxamethonium 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: suxamethonium 0.6 mg kg‐1
Trial: 444345
Drug: hexafluorenium 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hexafluorenium 0.3 mg kg‐1 with suxamethonium 1.0 mg kg‐1
Trial: 444345
Drug: hexafluorenium 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hexafluorenium 0.3 mg kg‐1
Trial: 444345
Drug: suxamethonium 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: suxamethonium 0.2 mg kg‐1 and 0.6 mg kg‐1 with or without hexafluorenium
Trial: 31406051
Drug: Sugammadex 1
RxNorm normalized name: sugammadex 100 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex 1 mg·kg‐1
Trial: 31406051
Drug: Sugammadex 2
RxNorm normalized name: sugammadex 200 MG in 2 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex 2 mg·kg‐1
Trial: 31406051
Drug: Sugammadex 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex 4 mg·kg‐1
Trial: 29547835
Drug: Tivozanib (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tivozanib (1.5 mg/day orally; 3 weeks on/1 week off)
Trial: 29547835
Drug: Sorafenib (previous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib (previous treatment)
Trial: 16084809
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (wait-listed, received treatment after follow-up).
Trial: 12641387
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (C‐group)
Trial: 8528637
Drug: HFX RT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HFX RT to a total dose of 64.8 Gy (Group 1)
Trial: 8528637
Drug: HFX RT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HFX RT with chemotherapy (100 mg carboplatin on days 1 and 2 and 100 mg etoposide on days 1-3 each week during RT) (Group 2)
Trial: 8528637
Drug: HFX RT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HFX RT with chemotherapy (200 mg carboplatin on days 1 and 2 and 100 mg etoposide on days 1-5 of the first, third, and fifth weeks) (Group 3)
Trial: 12283016
Drug: RU 486
RxNorm normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RU 486 (Mifepristone) 200 mg/day for 2 days before surgery
Trial: 7297145
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ASA and DPY (ASA-DPY)
Trial: 28960867
Drug: Left ventricular
RxNorm normalized name: DRESSING,VENTRICULAR ASSIST DEVICE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Left ventricular end‐diastolic volume >240 mL
Trial: 20864946
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (FA) treatment (5 mg/day for 4 weeks)